Considering the resistance to EGFR targeted therapy, the molecular basis and clinicopathological features of patients with NRAS‐mutation(+) CRC should be analyzed and clarified as previously performed for KRAS‐mutation(+) CRC. This evidence concerns the gene EGFR and colorectal carcinoma.